Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 USD | -1.17% | -4.33% | -38.91% |
16/04 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
02/04 | HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating | MT |
Business Summary
Number of employees: 57
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotheraphies
100.0
%
| 24 | 100.0 % | 2 | 100.0 % | -90.63% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 24 | 100.0 % | 2 | 100.0 % | -90.63% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 22/21/22 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 22/21/22 |
Michael King
DFI | Director of Finance/CFO | 63 | 30/23/30 |
Christoph Bausch
COO | Chief Operating Officer | 53 | 01/17/01 |
Chief Tech/Sci/R&D Officer | 51 | 06/22/06 | |
Melissa Ullerich
IRC | Investor Relations Contact | - | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 68 | 22/21/22 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 22/21/22 |
Erick Lucera
BRD | Director/Board Member | 57 | 03/23/03 |
David Link
BRD | Director/Board Member | 69 | 22/21/22 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 22/21/22 |
William Polvino
BRD | Director/Board Member | 63 | 22/21/22 |
Eddie Sullivan
FOU | Founder | 58 | 22/21/22 |
Andrew Moin
BRD | Director/Board Member | - | 05/23/05 |
Katie Ellias
BRD | Director/Board Member | - | 20/11 |
Scott Giberson
BRD | Director/Board Member | - | 11/22/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,280,160 | 7,460,413 ( 80.39 %) | 54,666 ( 0.5891 %) | 80.39 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.91% | 39.21M | |
-2.63% | 103B | |
+1.67% | 95.28B | |
+1.66% | 22.15B | |
-15.31% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.27% | 16.05B | |
+4.02% | 13.68B | |
+34.74% | 12.17B |
- Stock Market
- Equities
- SABS Stock
- Company SAB Biotherapeutics, Inc.